Biotech Values

[vinmantoo]

I saw the news today about the HSP90 inhibitor Debio 0932 from CRIS being moved into phase Ib. A week ago or so I attended an excellent seminar about HSP90 and its ability to allow genotypic variations to accumulate without engendering phenotypic variation. The genetic differences were uncovered when HSP90 was inhibited. I was also interested by some slides showing that HSP90 inhibitors had a dramatic effect on the stability of a mutant oncogenic kinase, specifically it dramatically decreased activity without altering protein levels.

This all got me to better appreciate why some think there is great potential in HSP90 inhibitors as anti-cancer agents. I would appreciate any insights from people who have been following this topic. I did do a quick google each and saw that SNTA has an HSP90 in phase II clinical trials. Thanks in advance.